Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/505Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Dowrick, Adam | - |
| dc.contributor.author | Wootten, Addie | - |
| dc.contributor.author | Murphy, Declan | - |
| dc.contributor.author | Costello, Anthony | - |
| dc.date | 2015-04 | - |
| dc.date.accessioned | 2015-12-10T04:11:58Z | - |
| dc.date.available | 2015-12-10T04:11:58Z | - |
| dc.date.issued | 2015-06 | - |
| dc.identifier.citation | Urology. 2015 Jun;85(6):1310-1. | en_US |
| dc.identifier.issn | 0090-4295 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11434/505 | - |
| dc.description.abstract | We appreciate the comments regarding our article. Although the need to measure outcome from the patients' perspective is being increasingly recognized across the surgical disciplines, it is important that those collecting such data use suitable instruments and understand how one can judge the appropriateness of one instrument over another. With localized prostate cancer having such a low mortality rate, it is understandable that morbidity and the assessment of quality of life measured from the patients' perspective is an important outcome measure in this patient group. | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.uri | http://www.ncbi.nlm.nih.gov/pubmed/25881861 | en_US |
| dc.subject | Australian Prostate Cancer Research Centre Epworth, Richmond, Victoria, Australia. | en_US |
| dc.subject | Questionnaires | en_US |
| dc.subject | Data Collection | en_US |
| dc.subject | Prostate Cancer | en_US |
| dc.subject | Cancer of the Prostate | en_US |
| dc.subject | Neoplasms, Prostate | en_US |
| dc.subject | Quality of Life | en_US |
| dc.subject | QoL | en_US |
| dc.subject | Morbidity | en_US |
| dc.subject | Outcomes Assessments, Patient | en_US |
| dc.subject | Patient Outcome Assessment | en_US |
| dc.subject | Assessment, Patient Outcomes | en_US |
| dc.subject | Outcome Measures | en_US |
| dc.subject | Sickness Impact Profile | en_US |
| dc.subject | Research Design | en_US |
| dc.title | (Refers to editorial comment made by Jonathan Bergman, and Mark S. Litwin, in Urology, available online 14th April 2015.) | en_US |
| dc.type | Comments | en_US |
| dc.identifier.doi | 10.1016/j.urology.2015.01.049. | en_US |
| dc.identifier.journaltitle | Urology | en_US |
| dc.description.affiliates | Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. | en_US |
| dc.description.affiliates | Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Norway. | en_US |
| dc.description.affiliates | Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. | en_US |
| dc.type.contenttype | Text | en_US |
| Appears in Collections: | Cancer Services Epworth Prostate Centre UroRenal, Vascular | |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.